![]() |
Market Research Report
Product code
1061934
Global Avelumab Market Insights and Forecast to 2028 |
Global Avelumab Market Insights and Forecast to 2028 |
Published: March 1, 2022
QYResearch
Content info: 78 Pages
Delivery time: 2-3 business days
|
Market Analysis and Insights: Global Avelumab Market
Due to the COVID-19 pandemic, the global Avelumab market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the review period. Fully considering the economic change by this health crisis, accounting for % of the Avelumab global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While Merkel-cell Carcinoma segment is altered to an % CAGR throughout this forecast period.
China Avelumab market size is valued at US$ million in 2021, while the US and Europe Avelumab are US$ million and US$ million, severally. The proportion of the US is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Avelumab landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period.
The global key manufacturers of Avelumab include Merck and Pfizer etc. In 2021, the global top five players have a share approximately % in terms of revenue.
Global Avelumab Scope and Segment
Avelumab market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Avelumab market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Segment by Application
By Company
By Region